DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

Information source: Rutgers, The State University of New Jersey
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Autism

Intervention: Aripiprazole (Drug)

Phase: N/A

Status: Completed

Sponsored by: University of Medicine and Dentistry of New Jersey

Official(s) and/or principal investigator(s):
Sherie L. Novotny, MD, Principal Investigator, Affiliation: Child and Adolescent Psychiatry, UMDNJ


Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale. (2) Aripiprazole treatment will be superior to placebo in the acute treatment of global autism severity. The purpose of this study is to examine the possible benefit of the medication Aripiprazole in autistic individuals.

Clinical Details

Official title: Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Clinical Global Impression Improvement (CGI-AD)

Aberrant Behavior Checklist

Detailed description: Aripiprazole is an atypical antipsychotic medication which is currently approved for the treatment of schizophrenia in adults. Multiple clinical trials in both children and adults have shown the effectiveness in the treatment of autism with medications like Aripiprazole. This study aims at assessing the effect of aripiprazole vs. placebo treatment on symptoms of irritability and aggression associated with autism, as well as the effect on the global severity of child and adolescent autistic disorder. Children or adolescent outpatients, with age ranges from 5-17, will be enrolled into an 8-week placebo controlled, double blind treatment study. During the 8 weeks, patients will be monitored by the treating psychiatrist. Study assessments will be administered at designated time points.


Minimum age: 5 Years. Maximum age: 17 Years. Gender(s): Both.


Inclusion Criteria:

- Meets DSM-IV, ADI-R criteria for autistic disorder.

- Age 5-17 years.

- Outpatients

- Parent or legal guardian willing to sign informed consent.

Exclusion Criteria:

- Subject has been diagnosed with a psychotic disorder (such as schizophrenia) or a

mood disorder, including depression or bipolar disorder (manic depression).

- Subject has caused visible harm to him/herself.

- Subject has an active seizure disorder or epilepsy (seizures within the past year).

- Subject has an unstable medical illness, including heart disease.

- Subject has experienced brain injury.

- Subject has a history of diabetes.

- Subject reports significant improvement of autism symptoms and behaviors to current

medication or other therapies.

- Subject has a history of prior treatment with Aripiprazole of 5 mg/day or higher for

6 weeks.

- Subject lives in a far away area and/or does not have regular access to

transportation to the clinical facility.

- Subject is a pregnant female or unwilling to use acceptable contraception if sexually


Locations and Contacts

Department of Child and Adolescent Psychiatry, University Behavioral Health Care Building, Piscataway, New Jersey 08854, United States
Additional Information

Official site of the Division of Child and Adolescent Psychiatry

Related publications:

Aman M, Smgh N, Stewart A, Field C. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.Am J Ment Defic, 1985a;89(5):485 491 Campbell M, et al, Neuroleptic related dyskinesias in autistic children: a prospective longitudinal study, J Am Acad Child Adolesc Psychiatry 1997; 36(6): 835 43. Fomboime E. The epidemiology of autism: a review. Psychological Medicine, 1999; 29:769 786. Guy W. ECDEU assessment manual for psychopharmacology. Revised. NTMH Publication DHEW Publ No (adm.) 76 388. Bethesda, MD: National Institute of Mental Health, 1976; 217 222. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open label study. J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):685 93. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, J Clin Psychiatry. 2001;62(l1).

Starting date: May 2006
Last updated: September 23, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017